top of page
  • mmahomed2

Associate for Research in Vision and Ophthalmology

Valitor presented the its first preclinical data at the 2018 Associate for Research in Vision and Ophthalmology conference in Baltimore, MD. This report demonstrated  a substantial increase in intravitreal half-life and extended efficacy for their lead Anti-VEGF compound intended to treat indications in ophthalmology.

10 views0 comments

Recent Posts

See All

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

bottom of page